The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Tom Andrus named chief digital officer at Prostate Cancer Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TOM ANDRUS was named chief digital officer and executive vice president of the Prostate Cancer Foundation.

Most recently, Andrus was general manager and senior vice president of AXS.com, a division of AEG, building a new ticketing company. Previously, he was senior vice president of product at MySpace, where he led the product, design, mobile, and search businesses.

Prior to joining MySpace, Andrus spent eight years at EarthLink where he created the company’s product management team, led business development, and established new divisions, launching the wireless, voice, cable and value-added services business units. He also led the Utilities product team at Symantec/Norton, and was one of the founding employees of Fitnesoft, a health management software company.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account